Forum Financial Management LP Purchases 65,399 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Forum Financial Management LP grew its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 133.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 114,324 shares of the company's stock after purchasing an additional 65,399 shares during the period. Forum Financial Management LP's holdings in Takeda Pharmaceutical were worth $1,514,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Blair William & Co. IL increased its position in shares of Takeda Pharmaceutical by 8.1% during the fourth quarter. Blair William & Co. IL now owns 12,199 shares of the company's stock worth $162,000 after acquiring an additional 913 shares in the last quarter. Vise Technologies Inc. increased its position in shares of Takeda Pharmaceutical by 3.1% during the fourth quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock worth $459,000 after acquiring an additional 1,026 shares in the last quarter. Sage Rhino Capital LLC increased its position in shares of Takeda Pharmaceutical by 14.9% during the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock worth $157,000 after acquiring an additional 1,538 shares in the last quarter. Vident Advisory LLC increased its position in shares of Takeda Pharmaceutical by 13.5% during the fourth quarter. Vident Advisory LLC now owns 13,606 shares of the company's stock worth $180,000 after acquiring an additional 1,616 shares in the last quarter. Finally, OLD Mission Capital LLC increased its position in shares of Takeda Pharmaceutical by 13.7% during the fourth quarter. OLD Mission Capital LLC now owns 13,977 shares of the company's stock worth $185,000 after acquiring an additional 1,687 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Up 1.2%

Takeda Pharmaceutical stock traded up $0.18 during mid-day trading on Friday, reaching $14.98. The company's stock had a trading volume of 640,414 shares, compared to its average volume of 1,930,818. The company has a market capitalization of $47.65 billion, a price-to-earnings ratio of 37.44, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 12 month low of $12.58 and a 12 month high of $15.43. The business's 50 day simple moving average is $14.66 and its 200 day simple moving average is $14.04. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). The business had revenue of $7.34 billion during the quarter, compared to the consensus estimate of $8.02 billion. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.